Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp WT (NQ: LEXXW )

0.6100 -0.0897 (-12.82%)
Streaming Delayed Price Updated: 9:43 AM EST, Nov 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,403
Open 0.6996
Bid (Size) 0.5000 (24)
Ask (Size) 0.7800 (13)
Prev. Close 0.6997
Today's Range 0.6100 - 0.6996
52wk Range 0.1700 - 2.500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Via ACCESSWIRE
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Via ACCESSWIRE

Performance

YTD
+22.00%
+22.00%
1 Month
-18.67%
-18.67%
3 Month
-44.55%
-44.55%
6 Month
-38.11%
-38.11%
1 Year
+103.81%
+103.81%

More News

Read More
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Via ACCESSWIRE
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Via ACCESSWIRE
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
Via ACCESSWIRE
Lexaria Welcomes Industry Veteran as New CEO
Via ACCESSWIRE
First Results from Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Lexaria Updates Current GLP-1 Market
Via ACCESSWIRE
Lexaria Appoints Michael Shankman as Chief Financial Officer
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Releases Strategic Letter from the Outgoing CEO
Via ACCESSWIRE
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Results from Lexaria's Molecular Characterization Study
Via ACCESSWIRE
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
Via ACCESSWIRE
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces First Results from Second GLP-1 Human Pilot Study ‘Reinforcing DehydraTECH’s Beneficial Delivery Kinetics’
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
Via CannabisNewsWire
Topics Regulatory Compliance
Exposures Legal Regulatory
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.